Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Review Article Volume 3 Issue 6

Highlighting the Journey So Far with Cancer and Chemotherapy

Kafayat Aderonke Yusuf and Kyoungtae Kim*

Department of Biology, Missouri State University, Springfield, Missouri, United States of America

*Corresponding Author: Kyoungtae Kim, Department of Biology, Missouri State University, Springfield, Missouri, United States of America.

Received: April 17, 2020; Published: May 22, 2020



  Cancer is one of the most deadly diseases in the world with thousands of deaths occurring globally from the disease. Despite several interventions, chemotherapy has proven to be one of the most effective treatment patterns used for majority of cancer types. This review is aimed at emphasizing the current updates with cancer chemotherapy suggesting the potentials for a new set of chemotherapy agents in cancer treatment.

Keywords: Cancer; Chemotherapy; Disease; Treatment



  1. Hejmadi M. “Introduction to Cancer Biology, 2nd edition”. Editionn (Denmark: Ventus Publishing) (2013).
  2. Ferlay J., et al. “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. International Journal of Cancer 136 (2015): E359-386.
  3. Sudhakar A. “History of Cancer, Ancient and Modern Treatment Methods”. Journal of Cancer Science and Clinical Therapeutics 1 (2009): 1-4.
  4. Basu AK. “DNA Damage, Mutagenesis and Cancer”. International Journal of Molecular Sciences (2018): 19.
  5. Vincent T., et al. “A History of Cancer Chemotherapy”. Cancer Research 68 (2008): 8643-8653.
  6. Hayes RB. “The carcinogenicity of metals in humans”. Cancer Causes Control 8 (1997): 371-385.
  7. Soehnge H., et al. “Mechanisms of induction of skin cancer by UV radiation”. Frontiers in Bioscience 2 (1997): d538-551.
  8. Stein CJ and Colditz GA. “Modifiable risk factors for cancer”. British Journal of Cancer 90 (2004): 299-303.
  9. Anand P., et al. “Cancer is a preventable disease that requires major lifestyle changes”. Pharmaceutical Research 25 (2008): 2097-2116.
  10. Senapati S., et al. “Controlled drug delivery vehicles for cancer treatment and their performance”. Signal Transduction and Targeted Therapy 3 (2018): 7.
  11. Chandarana H., et al. “Emerging Role of MRI in Radiation Therapy”. Journal of Magnetic Resonance Imaging6 (2018) 1-11.
  12. Housman G., et al. “Drug resistance in cancer: an overview”. Cancers (Basel) 6 (2014): 1769-1792.
  13. Florea AM and Busselberg D. “Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects”. Cancers (Basel) 3 (2011): 1351-1371.
  14. Frezza M., et al. “Novel metals and metal complexes as platforms for cancer therapy”. Current Pharmaceutical Design 16 (2010): 1813-1825.
  15. Bruijnincx PC and Sadler PJ. “New trends for metal complexes with anticancer activity”. Current Opinion in Chemical Biology 12 (2008): 197-206.
  16. Ji HF., et al. “Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia?” EMBO Reports 10 (2009): 194-200.
  17. Pranczk J., et al. “Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination”. Current Pharmaceutical Analysis 10 (2014): 2-9.
  18. Ndagi U., et al. “Metal complexes in cancer therapy - an update from drug design perspective”. Drug Design, Development and Therapy 11 (2017): 599-616.
  19. Dasari S and Tchounwou PB. “Cisplatin in cancer therapy: molecular mechanisms of action”. European Journal of Pharmacology 740 (2014): 364-378.
  20. Basu A and Krishnamurthy S. “Cellular responses to Cisplatin-induced DNA damage”. Journal of Nucleic Acids (2010).
  21. Abu-Surrah AS., et al. “Palladium-based chemotherapeutic agents: Routes toward complexes with good antitumor activity”. Cancer Therapy 6 (2008): 1-10.
  22. Ho GY., et al. “Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies”. Critical Reviews in Oncology/Hematology 102 (2016): 37-46.
  23. Jamieson ER and Lippard SJ. “Structure, Recognition, and Processing of Cisplatin-DNA Adducts”. Chemical Reviews 99 (1999): 2467-2498.
  24. Lee KB., et al. “Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II In vitro”. Proceedings of the National Academy of Sciences of the United States of America 99 (2002): 4239-4244.
  25. Kartalou M and Essigmann JM. “Recognition of cisplatin adducts by cellular proteins”. Mutation Research 478 (2001): 1-21.
  26. Kane SA and Lippard SJ. “Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins”. Biochemistry 35 (1996): 2180-2188.
  27. Yimit A., et al. “Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs”. Nature Communications 10 (2019): 309.
  28. Sakurai H., et al. “Antidiabetic vanadium(IV) and zinc(II) complexes”. Coordination Chemistry Reviews 226 (2002): 187-198.
  29. Kapdi AR and Fairlamb IJ. “Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes”. Chemical Society Reviews 43 (2014): 4751-4777.
  30. Ratcliff J., et al. “Part 1: Experimental and theoretical studies of 2-cyano-2-isonitroso-N-piperidynylacetamide (HPiPCO), 2-cyano-2-isonitroso-N-morphylacetamide (HMCO) and their Pt- and Pd- complexes”. Inorganica Chimica Acta 385 (2012b): 1-11.
  31. Mansuri-Torshizi H., et al. “Synthesis, spectroscopic, cytotoxic, and DNA binding studies of binuclear 2,2'-bipyridine-platinum(II) and -palladium(II) complexes of meso-alpha,alpha'-diaminoadipic and meso-alpha,alpha'-diaminosuberic acids”. Journal of Inorganic Biochemistry 45 (1992): 135-148.
  32. Chio IIC and Tuveson DA. “ROS in Cancer: The Burning Question”. Trends in Molecular Medicine 23 (2017): 411-429.
  33. Conklin KA. “Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness”. Integrative Cancer Therapies 3 (2004): 294-300.
  34. Yang H., et al. “The role of cellular reactive oxygen species in cancer chemotherapy”. Journal of Experimental and Clinical Cancer Research 37 (2018): 266.
  35. Pelicano H., et al. “ROS stress in cancer cells and therapeutic implications”. Drug Resistance Updates 7 (2004): 97-110.
  36. Li XX., et al. “Emodin as an effective agent in targeting cancer stem-like side population cells of gallbladder carcinoma”. Stem Cells and Development 22 (2013): 554-566.
  37. Wang H., et al. “Mechanisms of verapamil-enhanced chemosensitivity of gallbladder cancer cells to platinum drugs: glutathione reduction and MRP1 downregulation”. Oncology Reports 29 (2013): 676-684.
  38. Marullo R., et al. “Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions”. PLoS One 8 (2013): e81162.
  39. Moldogazieva NT., et al. “Reactive Oxygen and Nitrogen Species-Induced Protein Modifications: Implication in Carcinogenesis and Anticancer Therapy”. Cancer Research 78 (2018): 6040-6047.
  40. Xie K and Huang S. “Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency”. Free Radical Biology and Medicine 34 (2003): 969-986.
  41. Fukumura D., et al. “The role of nitric oxide in tumour progression”. Nature Reviews Cancer 6 (2006): 521-534.
  42. Lechner M., et al. “Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin”. Seminars in Cancer Biology 15 (2005): 277-289.
  43. Godoy LC., et al. “Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin”. Proceedings of the National Academy of Sciences of the United States of America 109 (2012): 20373-20378.
  44. Mayer IA and Arteaga CL. “The PI3K/AKT Pathway as a Target for Cancer Treatment”. Annual Review of Medicine 67 (2016): 11-28.
  45. Tang CH and Grimm EA. “Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines”. The Journal of Biological Chemistry 279 (2004): 288-298.
  46. Gerasimchuk N., et al. “Synthesis and characterization of disubstituted arylcyanoximes and their several metal complexes”. Inorganica Chimica Acta 361 (2008): 1983-2001.
  47. Ratcliff J., et al. “Part 2: In vitro cytotoxicity studies of two ML2 complexes (M=Pd, Pt; L=2-cyano-2-isonitroso-N-morpholylacetamide, HMCO) ”. Inorganica Chimica Acta 385 (2012a): 11-20.
  48. Marcano DC., et al. “The 2-Pyridylcyanoxime and its Complexes”. Current Inorganic Chemistry 5 (2015): 98-113.
  49. Eddings D., et al. “First bivalent palladium and platinum cyanoximates: synthesis, characterization, and biological activity”. Inorganic Chemistry 43 (2004): 3894-3909.
  50. Klaus DR., et al. “1D Polymeric Platinum Cyanoximate: A Strategy toward Luminescence in the Near-Infrared Region beyond 1000 nm”. Inorganic Chemistry 54 (2015): 1890-1900.


Citation: Kafayat Aderonke Yusuf and Kyoungtae Kim. “Highlighting the Journey So Far with Cancer and Chemotherapy". Acta Scientific Microbiology 3.6 (2020): 118-123.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US